glp-1 pancreatic cancer Research suggests popular diabetes drugs can cause abnormal growth in humans The study, unveiled at the

injectable therapy) and comorbidities/co-medication ( The triple therapy of metformin, a DPP-4 inhibitor and a SGLT-2 inhibitor has a very low treatment related hypoglycaemia risk, leads to a further, almost additive reduction of glycaemic parameters, a body weight loss in the same range as with a mono- or dual therapy with a SGLT-2 inhibitor and also to the expected SGLT-2 inhibitor induced reduction of blood pressure

[DOI] [PubMed] [Google Scholar] 101.Dubois J., Marchal A., Lacroix D., Cabou J

At the Soza Clinic, our goal is to support your health holistically whatever your journey is

Recently, the UGT3A1 enzyme has been shown to have a certain role in the metabolism of ursodeoxycholic acid used in therapy of cholestasis or gallstones (Mackenzie et al., 2008)